The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | COLUMBA: subcutaneous daratumumab vs. IV administration
Maria Victoria-Mateos
• 1 Jun 2019
Maria-Victoria Mateos, MD, PhD, of the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discusses the COLUMBA (NCT03277105) study which investigated subcutaneous daratumumab administration in patients with relapsed or refractory multiple myeloma vs. an IV administration. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
